Brett Kaplan, MD

Dr Kaplan is a biotech executive and board member with over 20 years of industry and financial experience. Dr Kaplan has raised over $1 billion in equity financings and advised on ~$150 billion in M&A transactions. He most recently was Chief Operating Officer at Climb Bio Inc. and previously served as President and Chief Financial and Corporate Development Officer of Chroma Medicine Inc.

Prior to Chroma, Dr Kaplan was the Chief Financial Officer of Prevail Therapeutics, which was acquired by Eli Lilly in January 2021 for up to $1.04 billion. Dr Kaplan previously served as Audit Committee Chair and board member of Compass Therapeutics.

Earlier in his career, Dr Kaplan was Managing Director at Evercore, where he spent eight years focused on biopharma M&A and equity financings. He began his career as an Equity Research Analyst at Cowen, covering large-cap pharmaceuticals, and held senior positions at Cubist and Lilly, where he focused on corporate and business development.

Dr Kaplan holds an MBBCh and an MBA from the University of Witwatersrand in South Africa.